YMTHE, Volume 27

Supplemental Information

miR-221/222-Mediated Inhibition of Autophagy

Promotes Dexamethasone Resistance

in Multiple Myeloma

Jian Xu, Yan Su, Aoshuang Xu, Fengjuan Fan, Shidai Mu, Lei Chen, Zhangbo Chu, Bo Zhang, Haifan Huang, Jiasi Zhang, Jun Deng, Lisha Ai, Chunyan Sun, and Yu Hu

Supplemental Information

Figure S1






Figure S1. Expression levels of miR-221 and miR-222 in MM cell lines.

(A-B) qRT-PCR analysis of miR-221 and miR-222 expression levels in MM cell lines. (C-D) qRT-PCR analysis of miR-221 and miR-222 expression levels in MM.1S cells 48 h after transfection with agomir-NC (1S+NC) or agomir-221/222 (1S+Ag-221/222). Nontransfected (1S) MM cells were used as controls.*** p<0.001. (E) qRT-PCR analysis of miR-221 and miR-222 expression levels in MM.1R cells transfected with antagomir-NC (AN-NC) or antagomir-221/222 (AN-221/222) for 48 h. Nontransfected MM.1R cells (1R) were used as controls. **p<0.01. (F-I) U266 and JJN3 cells were transfected with 100 nM of agomir-221/222 (Ag-221/222) or agomir-NC (Ag-NC). ARH-77 and H929 cells were transfected with 200 nM of antagomir-221/222 (AN-221/222) or antagomir-NC (AN-NC). Then the cells were treated with Dex at the indicated concentrations. After 48 h, cell viability was measured using CCK-8 assay. Data were shown as mean \pm SD from three independent experiments. **p<0.01.

Figure S2





(A) Western blot analysis of p62 and LC3B expression in U266, JJN3, ARH-77 and H929 cells after treatment with Dex for 24 h. (B) MM.1S and MM.1R cells expressing GFP-mCherry-LC3 fusion protein were treated with Dex for 24 h. The mean number of autophagosomes and autolysosomes per cell is represented by yellow and red, respectively. ** p<0.01. (C-D) Cell viability of U266 and JJN3 cells pretreated with autophagy inhibitor 3-MA or Ly294002 for 2h followed by Dex (10 μ M) for 48 h was assessed using CCK-8 assay. ** p<0.01.

Figure S3






Figure S3. miR-221/222 regulate the expression levels of ATG12 and p27 in MM cells.

(A-C) qRT-PCR and western blot analysis of ATG12 and p27 expression levels in MM cell lines. (D, E) qRT-PCR analysis of miR-221 and miR-222 expression levels in plasma cells (PCs) from patients with newly diagnosed MM (N-M) and patients with relapsed/refractory MM (R-M). (F) Correlations of miR-221 and miR-222 expression levels with ATG12 and p27 mRNA levels in MM patients were analyzed by way of Spearman correlation test. (G, H) qRT-PCR analysis of ATG12 and p27 mRNA levels in MM.1S cells transfected with agomir-NC (NC) or agomir-221/222 (Ag-221/222). (I, J) qRT-PCR analysis of relative mRNA levels of ATG12 and p27 in MM.1R cells transfected with antagomir-NC (AN-NC) or antagomir-221/222 (AN-221/222). * p<0.05

Figure S4





(A) MM.1R cells expressing GFP-mCherry-LC3 fusion protein were co-transfected with antagomir-221/222 and siRNAs targeting ATG12 or p27 for 48 h. The mean number of autophagosomes and autolysosomes per MM.1R cell is represented by yellow and red, respectively. **p<0.01. (B-E) qRT-PCR and western blot analysis of ATG12 and p27 expression levels in MM.1S cells transfected with siRNA targeting ATG12 or p27. **p<0.01. (F, G) Western blot analysis of pmTOR, mTOR, LC3B and p62 protein expression in MM.1S cells transfected with p27 siRNA, ATG12 siRNA or siRNA-NC for 72 h. (H) Representative confocal images of MM.1S cells expressing GFP-mCherry-LC3 fusion protein and transfected with p27 siRNA, ATG12 siRNA or siRNA-NC for 48 h. (I) The mean number of autophagosomes and autolysosomes per MM.1S cell is represented by yellow and red, respectively. **p<0.01.

Figure S5




Figure S5. Knockdown of ATG12 or p27 inhibits Dex-induced autophagic cell death in MM cells. (A) MM.1R cells co-transfected with antagomir-221/222 or antagomir-NC and siRNA targeting ATG12 or p27 were treated with Dex (50 μ M) for 48 h. Apoptosis was examined by detecting cleavage of caspase-3 and PARP using western blot analysis. (B-C) MM.1R cells transfected with antagomir-NC or antagomir-221/222 were pretreated with pan-caspase inhibitor z-VAD-fmk (50 μ M) for 2 h followed by Dex (50 μ M) for 48 h. Apoptosis was examined by detecting cleavage of caspase-3 and PARP with western blot analysis (B) and cell viability was assessed using CCK-8 assay (C). (D-E) MM.1S cells transfected with siRNA targeting p27 or ATG12 were treated with Dex (1 μ M). After 48 h, cell viability was evaluated using CCK-8 assay (D) and apoptosis was examined by detecting cleavage of caspase-3 and PARP using western blotting (E). * p<0.05, ** p<0.01.

Figure S6




Figure S6. qRT-PCR analysis of miR-221 and miR-222 expression levels in tumor tissues from MM.1R-xenografted mice treated with antagomir-NC and antagomir-221/222. **p<0.01.

	Number	Gender,	Age,	Isotype	International
		Male/Female	median		Staging System
			(range)		(ISS) stage
			years		
Healthy	11	7/4	57	-	-
donor			(37-70)		
Newly	20	14/6	59	11 IgG Kappa	ISS I: 2
diagnosed			(45-76)	3 IgG Lambda	ISS II: 7
MM				2 IgA Kappa	ISS III: 11
				2 IgA Lambda	
				1 IgD Lambda	
				1 Lambda	
Relapsed/	21	15/6	60	10 IgG Kappa	ISS I: 2
Refractory			(42-80)	2 IgG Lambda	ISS II: 6
MM				4 IgA Kappa	ISS III: 13
				3 IgA Lambda	
				2 IgD Lambda	

Table S1. Clinical information of healthy donors and MM patients .

Table S2. Dex sensitivity of MM cell lines.

5		
MM cell lines	IC50 (mean±SD)	Dex sensitivity
MM.1S	$0.091\pm0.02~\mu M$	Sensitive
U266	$2.02\pm0.504~\mu M$	Sensitive
JJN3	$4.021\pm0.602~\mu M$	Sensitive
RPMI 8226	$14.96\pm1.873~\mu M$	Sensitive
H929	>500 µM	Resistant
MR20	>500 µM	Resistant
MM.1R	>500 µM	Resistant
ARH-77	>500 µM	Resistant

MM Cells were seeded in 96-well plates (3 \times 10⁴ cells/well) in the presence of different concentrations of Dex. After 48 h, CCK-8 assay was performed. The concentration at which Dex produced IC50 was then calculated. Dex sensitivity was defined as follow: sensitive, IC50 < 50 μ M.

Table 55. I finiters for qitti-i Cit used in this study.				
Prime name	Sequence			
ATG12 forward	5'-CCACTGAGGGTTCAGATGATAGA-3'			
ATG12 reverse	5'-TGGGCAACAAGACCGAAAC-3'			
p27 forward	5'-GCAGGAGAGCCAGGATGTCAG-3'			
p27 reverse	5'-TGCGTGTCCTCAGAGTTAGCC-3'			
GAPDH forward	5'-GGTGAAGGTCGGAGTCAACGG-3'			
GAPDH reverse	5'-CCTGGAAGATGGTGATGGGATT-3'			

Table S3. Primers for gRT-PCR used in this study.

Table 54. she fix sequences of genes used in this study.				
Sequence				
5'-AGAAGTTGGAACTCTCTAT-3'				
5'-GGGATGAACCACAAAGAAA-3'				
5'-AAGTGGGCAGTAGAGCGAACACGAA-3'				
5'-GGAGCAATGCGCAGGAATA-3'				
5'-GCAAGTACGAGTGGCAAGA-3'				
5'-GCACTGCAGAGACATGGAA-3'				
5'-TTCTCCGAACGTGTCACGT-3'				

Table S4. siRNA sequences of genes used in this study.